Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Maria I. Pacheco"'
Autor:
Rebeca Lozano, David Lorente, Isabel M. Aragon, Nuria Romero-Laorden, Paz Nombela, Joaquim Mateo, Alison H. M. Reid, Ylenia Cendón, Diletta Bianchini, Casilda Llacer, Shahneen K. Sandhu, Adam Sharp, Pasquale Rescigno, Teresa Garcés, Maria I. Pacheco, Penelope Flohr, Christophe Massard, Pedro P. López-Casas, Elena Castro, Johann S. de Bono, David Olmos
Publikováno v:
Cancers, Vol 13, Iss 10, p 2334 (2021)
Circulating tumor cell (CTC) enumeration and changes following treatment have been demonstrated to be superior to PSA response in determining mCRPC outcome in patients receiving AR signaling inhibitors but not taxanes. We carried out a pooled analysi
Externí odkaz:
https://doaj.org/article/25aa60de536743f59f084ad791f71abd
Autor:
Casilda Llácer, Heather Thorne, José Rubio-Briones, David Lorente, Rebeca Lozano, Pedro P. López-Casas, Emmanuel S. Antonarakis, Fernando López-Campos, Tamara L. Lotan, Francisco Zambrana, Colin C. Pritchard, Teresa Garcés, Alejandro Sanz, Nuria Romero-Laorden, Ana M. Gutierrez-Pecharroman, David Olmos, Laneisha Maldonado, Isabel M. Aragón, Isabel García, Shahneen Sandhu, Juan Daniel Prieto, Elena Castro, Joaquin Mateo, Tomas di Domenico, Maria I Pacheco, Daniela C. Salles
Publikováno v:
European Journal Of Cancer
r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón
Banco de España
r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón
Banco de España
Background: Intraductal (IDC) and cribriform (CRIB) histologies in prostate cancer have been associated with germline BRCA2 (gBRCA2) mutations in small retrospective series, leading to the recommendation of genetic testing for patients with IDC in th
Autor:
Isabel M. Aragón, Vincenza Conteduca, Javier de la Puente, P. Borrega García, R. Morales Barrera, D. Olmos Hidalgo, U. De Giorgi, R. Lozano Mejorada, Maria I Pacheco, G.A. De Velasco Oria de Rueda, L. Magraner, M.I. Sáez, Enrique A. Castro, David Lorente, A. González del Alba, E.M. Fernandez Parra, A Medina Colmenero, N. Romero Laorden, Alejo Rodriguez-Vida, J.C. Villa Guzman
Publikováno v:
Annals of Oncology. 30:v343-v344
Background Ra223 is a bone-seeking a-emitter targeted therapy that induces double-strand DNA breaks (DSBs). The HR pathway is used to accurately repair DSBs and a significant proportion of mCRPC patients harbor pathogenic germline HR mutations (gHR+)
Autor:
Maria I Pacheco, Lucía Oliva, R. Villatoro, Elena Castro, Bella Pajares, Ana Otero, Bernardo Herrera-Imbroda, Raquel Correa, Francisco Javier Machuca, Gala Grau, Antonia Márquez-Aragonés, Rebeca Lozano, A. Montesa, María Isabel Sáez, David Olmos, Pablo Peinado, Casilda Llácer, Isabel M. Aragón, Emilio Alba, Emilio García-Galisteo, David Marín Hernández, Antonio Rueda
Publikováno v:
European urology oncology. 4(2)
Early identification of germline BRCA1/2 mutations may be relevant for the management of patients with prostate cancer (PC) and to prevent future breast and ovarian cancers in their relatives. Several prediction tools have been developed to estimate
Autor:
David Lorente, Alexander W. Wyatt, Muhammad Zulfiqar, Isabel M. Aragón, Daygen Finch, Rebeca Lozano, Joanna Vergidis, Sinja Taavitsainen, Matti Annala, Conrad D. Oja, Martin E. Gleave, Ylenia Cendon, Nuria Romero-Laorden, Kim N. Chi, Elena Castro, Maria I Pacheco, Daniel Khalaf, David Olmos
Publikováno v:
Journal of Clinical Oncology. 38:5525-5525
5525 Background: The common HSD3B1 (1245A > C) germline variant is associated with increased de-novo synthesis of androgens and worse outcomes in men treated with androgen-deprivation therapy in metastatic hormone sensitive prostate cancer. The aim o
Autor:
Isabel García, Isabel M. Aragón, Elena Castro, Shahneen Sandhu, Francisco Zambrana, Fernando Lopez Campos, Jose Rubio, David Olmos, Daniela C. Salles, Tamara L. Lotan, Maria I Pacheco, Emmanuel S. Antonarakis, Casilda Llacer Perez, Rebeca Lozano, Ana Gutierrez Pecharroman, Daniel Prieto, Pedro P. López-Casas, Heather Thorne, Nuria Romero-Laorden, Laneisha Maldonado
Publikováno v:
Journal of Clinical Oncology. 38:5579-5579
5579 Background: IDC histology in PC has been suggested to associate with germline BRCA2 mutations (gBRCA2) in small series, leading to the potential recommendation of genetic testing for all PC patients with IDC in the primary tumor. Methods: We con
Autor:
Paz Nombela, Pasquale Rescigno, R. Lozano Mejorada, David Lorente, Diletta Bianchini, Shahneen Sandhu, N. Romero Laorden, Casilda Llácer, Enrique A. Castro, Maria I Pacheco, Claudia L. Moreno, Joaquin Mateo, M.I. Sáez, J.S. de Bono, F.M. Vitrone, D. Olmos Hidalgo, L. Rivera, Ylenia Cendon, E. Almagro Casado, Adam Sharp
Publikováno v:
Annals of Oncology. 30:v350
Background Clinically meaningful measures of response are needed in mCRPC. Post-treatment CTC decline have shown to be superior to PSA response in determining outcome in pts treated with AR signalling inhibitors. We compared the performance of CTC an
Autor:
Elena Piñeiro-Yáñez, Nuria Romero-Laorden, A. Gutierrez-Pecharroman, Maria I Pacheco, Fatima Al-Shahrour, Elena Castro, David Olmos, E. Calvo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4c8e98c2d6e71e53bd5d70911e549cf
https://hdl.handle.net/10668/11146
https://hdl.handle.net/10668/11146
Autor:
L. San Jose, Isabel M. Aragón, Maria I Pacheco, R. Colomer Bosch, I. Hernandez, Nuria Romero-Laorden, T. González, R. Lozano Mejorada, L. Rivera, Almudena Zapatero
Publikováno v:
Annals of Oncology. 29:vi19-vi20